Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$868M |
| 2 |
Amazon
AMZN
|
+$726M |
| 3 |
UnitedHealth
UNH
|
+$571M |
| 4 |
Rivian
RIVN
|
+$559M |
| 5 |
TJX Companies
TJX
|
+$441M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.09B |
| 2 |
NVIDIA
NVDA
|
+$762M |
| 3 |
L3Harris
LHX
|
+$742M |
| 4 |
Zurn Elkay Water Solutions
ZWS
|
+$497M |
| 5 |
Texas Instruments
TXN
|
+$477M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.51% |
| 2 | Healthcare | 18.41% |
| 3 | Consumer Discretionary | 11.39% |
| 4 | Financials | 9.7% |
| 5 | Industrials | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRUE
2526
DELISTED
TrueCar
TRUE
| $65K | ﹤0.01% |
+19,005
| New | +$72.3K |
|
|
AUD
2527
DELISTED
Audacy, Inc.
AUD
| $64K | ﹤0.01% |
25,007
+12,569
| +101% | +$38.7K |
|
2528
Viking Therapeutics
VKTX
$3.88B
| $62K | ﹤0.01% |
+13,409
| New | +$75.2K |
|
2529
Geron
GERN
$898M
| $60K | ﹤0.01% |
49,025
+24,741
| +102% | +$35.4K |
|
2530
RPC Inc
RES
$1.13B
| $60K | ﹤0.01% |
+13,154
| New | +$64.6K |
|
2531
New Oriental
EDU
$9.32B
| $57K | ﹤0.01% |
2,699
| – | – |
|
2532
Standard BioTools
LAB
$342M
| $56K | ﹤0.01% |
+14,407
| New | +$67.4K |
|
|
CLVS
2533
DELISTED
Clovis Oncology, Inc.
CLVS
| $55K | ﹤0.01% |
20,270
+10,239
| +102% | +$37.8K |
|
|
ZOM
2534
DELISTED
Zomedica Corp.
ZOM
| $55K | ﹤0.01% |
177,068
+88,139
| +99% | +$39.7K |
|
|
BDSI
2535
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $54K | ﹤0.01% |
+17,444
| New | +$58.7K |
|
|
SDC
2536
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $49K | ﹤0.01% |
20,830
+10,489
| +101% | +$43.8K |
|
2537
Alaunos Therapeutics
TCRT
$4.64M
| $48K | ﹤0.01% |
290
+146
| +101% | +$32.1K |
|
2538
Lexicon Pharmaceuticals
LXRX
$1.03B
| $46K | ﹤0.01% |
+11,786
| New | +$57.2K |
|
|
GOCO
2539
DELISTED
GoHealth
GOCO
| $38K | ﹤0.01% |
+673
| New | +$44.9K |
|
|
EPZM
2540
DELISTED
Epizyme, Inc
EPZM
| $36K | ﹤0.01% |
+14,529
| New | +$57.1K |
|
|
ALLK
2541
DELISTED
Allakos
ALLK
| – | – |
-983,329
| Closed | -$104M |
|
2542
Allogene Therapeutics
ALLO
$625M
| – | – |
-7,795
| Closed | -$200K |
|
2543
Arvinas
ARVN
$530M
| – | – |
-3,608
| Closed | -$296K |
|
2544
Asana
ASAN
$1.96B
| – | – |
-6,459
| Closed | -$671K |
|
2545
JPMorgan BetaBuilders Developed Asia Pacific-ex Japan ETF
BBAX
$6.66B
| – | – |
-166,591
| Closed | -$9.03M |
|
2546
Bilibili
BILI
$7.75B
| – | – |
-13,268
| Closed | -$878K |
|
2547
CNA Financial
CNA
$14.9B
| – | – |
-26,069
| Closed | -$1.09M |
|
2548
Copa Holdings
CPA
$5.56B
| – | – |
-17,857
| Closed | -$1.45M |
|
2549
DraftKings
DKNG
$12.2B
| – | – |
-20,832
| Closed | -$1M |
|
2550
Doximity
DOCS
$3.89B
| – | – |
-71,076
| Closed | -$5.74M |
|
Similar funds
Janus Henderson Group's Q4 2021 Portfolio in Review
As of Q4 2021, Janus Henderson Group held 2,654 positions worth $240B, up 4.9% from $229B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Janus Henderson Group's Q4 2021 filing shows 464 new, 1,324 increased, 690 reduced and 110 closed positions. Its largest new stake was Rivian: 4,856,003 shares worth $504M. The largest sale was Meta Platforms (Facebook), an estimated $1.09B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2021 buy was Rivian: 4,856,003 shares worth $504M.
- Janus Henderson Group added most to Apple in Q4 2021, an estimated $868M increase.
- Janus Henderson Group's biggest Q4 2021 reduction was Meta Platforms (Facebook), cutting an estimated $1.09B.
- Janus Henderson Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $274M.
- Janus Henderson Group's ten largest holdings make up 25% of its $240B portfolio in Q4 2021.
- Janus Henderson Group opened 464 new positions and closed 110 in Q4 2021.
- Janus Henderson Group's portfolio value rose 4.9% quarter-over-quarter to $240B.
Based on Janus Henderson Group's 13F filing for Q4 2021, filed 14 Feb 2022.